Annual FCF
-$19.20 M
$0.000.00%
31 December 2023
Summary:
Theriva Biologics annual free cash flow is currently -$19.20 million, unchanged on 31 December 2023. During the last 3 years, it has fallen by -$7.02 million (-57.66%). TOVX annual FCF is now -1674.14% below its all-time high of -$1.08 million, reached on 01 December 2005.TOVX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$3.91 M
-$460.00 K-13.32%
01 September 2024
Summary:
Theriva Biologics quarterly free cash flow is currently -$3.91 million, with the most recent change of -$460.00 thousand (-13.32%) on 01 September 2024. Over the past year, it has dropped by -$831.00 thousand (-26.96%). TOVX quarterly FCF is now -182.68% below its all-time high of $4.73 million, reached on 01 June 2001.TOVX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$18.84 M
-$831.00 K-4.61%
01 September 2024
Summary:
Theriva Biologics TTM free cash flow is currently -$18.84 million, with the most recent change of -$831.00 thousand (-4.61%) on 01 September 2024. Over the past year, it has dropped by -$784.00 thousand (-4.34%). TOVX TTM FCF is now -4611.00% below its all-time high of -$400.00 thousand, reached on 01 March 1993.TOVX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TOVX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | 0.0% | -27.0% | -4.3% |
| 3 y3 years | -57.7% | +18.6% | -46.0% |
| 5 y5 years | -38.4% | -8.5% | -35.8% |
TOVX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -57.7% | at low | -27.0% | +40.7% | -46.0% | +5.4% |
| 5 y | 5 years | -57.7% | at low | -93.1% | +40.7% | -78.5% | +5.4% |
| alltime | all time | -1674.1% | +51.3% | -182.7% | +74.9% | -4611.0% | +52.5% |
Theriva Biologics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.91 M(+13.3%) | -$18.84 M(+4.6%) |
| June 2024 | - | -$3.45 M(-29.3%) | -$18.01 M(-2.4%) |
| Mar 2024 | - | -$4.88 M(-26.0%) | -$18.46 M(-3.8%) |
| Dec 2023 | -$19.20 M(0.0%) | -$6.60 M(+114.0%) | -$19.20 M(+6.3%) |
| Sept 2023 | - | -$3.08 M(-21.0%) | -$18.06 M(-7.1%) |
| June 2023 | - | -$3.90 M(-30.6%) | -$19.45 M(-2.4%) |
| Mar 2023 | - | -$5.62 M(+2.9%) | -$19.91 M(+3.7%) |
| Dec 2022 | -$19.20 M(+48.8%) | -$5.46 M(+22.2%) | -$19.20 M(+3.5%) |
| Sept 2022 | - | -$4.47 M(+2.2%) | -$18.55 M(+14.2%) |
| June 2022 | - | -$4.37 M(-10.9%) | -$16.24 M(+12.3%) |
| Mar 2022 | - | -$4.90 M(+1.9%) | -$14.46 M(+12.1%) |
| Dec 2021 | -$12.90 M(+6.0%) | - | - |
| Dec 2021 | - | -$4.81 M(+123.1%) | -$12.90 M(+14.9%) |
| Sept 2021 | - | -$2.16 M(-16.9%) | -$11.23 M(+0.9%) |
| June 2021 | - | -$2.60 M(-22.3%) | -$11.13 M(+5.4%) |
| Mar 2021 | - | -$3.34 M(+6.5%) | -$10.56 M(-13.3%) |
| Dec 2020 | -$12.18 M(-12.2%) | -$3.14 M(+52.7%) | -$12.18 M(-3.7%) |
| Sept 2020 | - | -$2.05 M(+1.4%) | -$12.64 M(-7.4%) |
| June 2020 | - | -$2.03 M(-59.2%) | -$13.65 M(-6.5%) |
| Mar 2020 | - | -$4.96 M(+37.6%) | -$14.61 M(+5.3%) |
| Dec 2019 | -$13.87 M(-19.7%) | -$3.60 M(+17.7%) | -$13.87 M(+2.3%) |
| Sept 2019 | - | -$3.06 M(+2.7%) | -$13.56 M(-3.8%) |
| June 2019 | - | -$2.98 M(-29.4%) | -$14.10 M(-8.6%) |
| Mar 2019 | - | -$4.22 M(+28.4%) | -$15.42 M(-10.7%) |
| Dec 2018 | -$17.29 M(-15.3%) | -$3.29 M(-8.7%) | -$17.28 M(-3.6%) |
| Sept 2018 | - | -$3.60 M(-16.4%) | -$17.92 M(-5.9%) |
| June 2018 | - | -$4.31 M(-29.1%) | -$19.04 M(-7.0%) |
| Mar 2018 | - | -$6.08 M(+54.5%) | -$20.48 M(+0.3%) |
| Dec 2017 | -$20.42 M(-28.3%) | -$3.94 M(-16.7%) | -$20.42 M(-25.0%) |
| Sept 2017 | - | -$4.72 M(-17.7%) | -$27.23 M(-4.9%) |
| June 2017 | - | -$5.74 M(-4.6%) | -$28.65 M(-0.4%) |
| Mar 2017 | - | -$6.02 M(-44.0%) | -$28.77 M(+1.1%) |
| Dec 2016 | -$28.47 M(-27.7%) | -$10.75 M(+75.2%) | -$28.47 M(-0.9%) |
| Sept 2016 | - | -$6.14 M(+4.7%) | -$28.73 M(-24.8%) |
| June 2016 | - | -$5.86 M(+2.5%) | -$38.20 M(-3.6%) |
| Mar 2016 | - | -$5.72 M(-48.1%) | -$39.63 M(+0.6%) |
| Dec 2015 | -$39.39 M(+144.3%) | -$11.01 M(-29.4%) | -$39.39 M(+18.8%) |
| Sept 2015 | - | -$15.61 M(+114.0%) | -$33.16 M(+50.0%) |
| June 2015 | - | -$7.29 M(+33.2%) | -$22.11 M(+22.0%) |
| Mar 2015 | - | -$5.48 M(+14.5%) | -$18.13 M(+12.4%) |
| Dec 2014 | -$16.13 M(+108.0%) | -$4.78 M(+5.0%) | -$16.13 M(+14.7%) |
| Sept 2014 | - | -$4.56 M(+37.6%) | -$14.06 M(+25.1%) |
| June 2014 | - | -$3.31 M(-4.7%) | -$11.23 M(+17.5%) |
| Mar 2014 | - | -$3.47 M(+28.0%) | -$9.56 M(+23.3%) |
| Dec 2013 | -$7.75 M(-13.1%) | -$2.71 M(+56.8%) | -$7.75 M(-21.0%) |
| Sept 2013 | - | -$1.73 M(+5.4%) | -$9.82 M(+3.0%) |
| June 2013 | - | -$1.64 M(-1.3%) | -$9.53 M(+3.9%) |
| Mar 2013 | - | -$1.67 M(-65.1%) | -$9.18 M(+2.8%) |
| Dec 2012 | -$8.93 M(+210.5%) | -$4.78 M(+229.6%) | -$8.93 M(+82.9%) |
| Sept 2012 | - | -$1.45 M(+12.7%) | -$4.88 M(+12.4%) |
| June 2012 | - | -$1.29 M(-9.1%) | -$4.34 M(+8.3%) |
| Mar 2012 | - | -$1.42 M(+93.6%) | -$4.01 M(+39.4%) |
| Dec 2011 | -$2.88 M(+148.5%) | -$731.00 K(-19.8%) | -$2.88 M(+2.0%) |
| Sept 2011 | - | -$911.00 K(-4.3%) | -$2.82 M(+0.5%) |
| June 2011 | - | -$952.00 K(+238.8%) | -$2.80 M(+362.6%) |
| Mar 2011 | - | -$281.00 K(-58.4%) | -$606.10 K(-47.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$1.16 M(-60.4%) | -$675.10 K(-24.6%) | -$1.16 M(-6.5%) |
| Sept 2010 | - | -$895.90 K(-171.9%) | -$1.24 M(+18.3%) |
| June 2010 | - | $1.25 M(-249.8%) | -$1.05 M(-67.1%) |
| Mar 2010 | - | -$831.90 K(+10.1%) | -$3.18 M(+9.1%) |
| Dec 2009 | -$2.92 M(-40.1%) | -$755.50 K(+7.3%) | -$2.92 M(+1.5%) |
| Sept 2009 | - | -$704.30 K(-21.0%) | -$2.87 M(-9.9%) |
| June 2009 | - | -$891.70 K(+57.2%) | -$3.19 M(-11.6%) |
| Mar 2009 | - | -$567.30 K(-20.3%) | -$3.61 M(-26.0%) |
| Dec 2008 | -$4.87 M(-43.2%) | -$711.40 K(-30.2%) | -$4.87 M(-26.3%) |
| Sept 2008 | - | -$1.02 M(-22.2%) | -$6.61 M(-18.0%) |
| June 2008 | - | -$1.31 M(-28.6%) | -$8.06 M(-5.8%) |
| Mar 2008 | - | -$1.83 M(-25.1%) | -$8.56 M(-0.2%) |
| Dec 2007 | -$8.57 M(+255.5%) | -$2.45 M(-0.8%) | -$8.57 M(+26.8%) |
| Sept 2007 | - | -$2.47 M(+37.1%) | -$6.76 M(+36.5%) |
| June 2007 | - | -$1.80 M(-2.6%) | -$4.95 M(+32.3%) |
| Mar 2007 | - | -$1.85 M(+189.6%) | -$3.74 M(+55.2%) |
| Dec 2006 | -$2.41 M(+122.9%) | -$639.20 K(-3.2%) | -$2.41 M(+36.1%) |
| Sept 2006 | - | -$660.10 K(+11.3%) | -$1.77 M(+59.3%) |
| June 2006 | - | -$593.10 K(+14.2%) | -$1.11 M(+114.2%) |
| Mar 2006 | - | -$519.20 K(+10.0%) | -$519.20 K(-88.5%) |
| Dec 2005 | -$1.08 M(-81.5%) | - | - |
| Mar 2003 | - | -$471.80 K(+27.9%) | -$4.51 M(-23.0%) |
| Dec 2002 | -$5.86 M(-29.2%) | -$368.80 K(-62.4%) | -$5.86 M(-29.5%) |
| Sept 2002 | - | -$980.60 K(-63.5%) | -$8.30 M(-15.8%) |
| June 2002 | - | -$2.69 M(+48.0%) | -$9.86 M(+304.9%) |
| Mar 2002 | - | -$1.82 M(-35.5%) | -$2.43 M(-70.6%) |
| Dec 2001 | -$8.27 M(+44.2%) | -$2.82 M(+11.2%) | -$8.27 M(+25.6%) |
| Sept 2001 | - | -$2.53 M(-153.5%) | -$6.58 M(+24.1%) |
| June 2001 | - | $4.73 M(-161.9%) | -$5.30 M(-54.0%) |
| Mar 2001 | - | -$7.65 M(+577.7%) | -$11.53 M(+101.1%) |
| Dec 2000 | -$5.73 M(-64.8%) | -$1.13 M(-10.0%) | -$5.73 M(-67.6%) |
| Sept 2000 | - | -$1.25 M(-16.1%) | -$17.68 M(-1.9%) |
| June 2000 | - | -$1.50 M(-19.3%) | -$18.03 M(+5.8%) |
| Mar 2000 | - | -$1.85 M(-85.8%) | -$17.03 M(+4.6%) |
| Dec 1999 | -$16.28 M(-13.4%) | -$13.08 M(+717.5%) | -$16.28 M(+317.4%) |
| Sept 1999 | - | -$1.60 M(+219.3%) | -$3.90 M(-11.4%) |
| June 1999 | - | -$501.10 K(-54.4%) | -$4.40 M(-77.3%) |
| Mar 1999 | - | -$1.10 M(+57.0%) | -$19.40 M(+3.2%) |
| Dec 1998 | -$18.80 M(+176.5%) | -$700.00 K(-66.7%) | -$18.80 M(0.0%) |
| Sept 1998 | - | -$2.10 M(-86.5%) | -$18.80 M(+3.9%) |
| June 1998 | - | -$15.50 M(+3000.0%) | -$18.10 M(+262.0%) |
| Mar 1998 | - | -$500.00 K(-28.6%) | -$5.00 M(-25.4%) |
| Dec 1997 | -$6.80 M(+11.5%) | -$700.00 K(-50.0%) | -$6.70 M(-8.2%) |
| Sept 1997 | - | -$1.40 M(-41.7%) | -$7.30 M(-3.9%) |
| June 1997 | - | -$2.40 M(+9.1%) | -$7.60 M(+16.9%) |
| Mar 1997 | - | -$2.20 M(+69.2%) | -$6.50 M(+8.3%) |
| Dec 1996 | -$6.10 M(-18.7%) | -$1.30 M(-23.5%) | -$6.00 M(+27.7%) |
| Sept 1996 | - | -$1.70 M(+30.8%) | -$4.70 M(+56.7%) |
| June 1996 | - | -$1.30 M(-23.5%) | -$3.00 M(+76.5%) |
| Mar 1996 | - | -$1.70 M(+325.0%) | -$1.70 M(-51.4%) |
| Dec 1995 | -$7.50 M(+66.7%) | - | - |
| Dec 1994 | -$4.50 M(+28.6%) | - | - |
| Mar 1994 | - | -$400.00 K(-150.0%) | -$3.50 M(0.0%) |
| Dec 1993 | -$3.50 M | $800.00 K(-123.5%) | -$3.50 M(-18.6%) |
| Sept 1993 | - | -$3.40 M(+580.0%) | -$4.30 M(+377.8%) |
| June 1993 | - | -$500.00 K(+25.0%) | -$900.00 K(+125.0%) |
| Mar 1993 | - | -$400.00 K | -$400.00 K |
FAQ
- What is Theriva Biologics annual free cash flow?
- What is the all time high annual FCF for Theriva Biologics?
- What is Theriva Biologics annual FCF year-on-year change?
- What is Theriva Biologics quarterly free cash flow?
- What is the all time high quarterly FCF for Theriva Biologics?
- What is Theriva Biologics quarterly FCF year-on-year change?
- What is Theriva Biologics TTM free cash flow?
- What is the all time high TTM FCF for Theriva Biologics?
- What is Theriva Biologics TTM FCF year-on-year change?
What is Theriva Biologics annual free cash flow?
The current annual FCF of TOVX is -$19.20 M
What is the all time high annual FCF for Theriva Biologics?
Theriva Biologics all-time high annual free cash flow is -$1.08 M
What is Theriva Biologics annual FCF year-on-year change?
Over the past year, TOVX annual free cash flow has changed by $0.00 (0.00%)
What is Theriva Biologics quarterly free cash flow?
The current quarterly FCF of TOVX is -$3.91 M
What is the all time high quarterly FCF for Theriva Biologics?
Theriva Biologics all-time high quarterly free cash flow is $4.73 M
What is Theriva Biologics quarterly FCF year-on-year change?
Over the past year, TOVX quarterly free cash flow has changed by -$831.00 K (-26.96%)
What is Theriva Biologics TTM free cash flow?
The current TTM FCF of TOVX is -$18.84 M
What is the all time high TTM FCF for Theriva Biologics?
Theriva Biologics all-time high TTM free cash flow is -$400.00 K
What is Theriva Biologics TTM FCF year-on-year change?
Over the past year, TOVX TTM free cash flow has changed by -$784.00 K (-4.34%)